3,4,5,6-Tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats

Cardiovascular Drugs and Therapy
Zhong DaiYuan-Jian Li

Abstract

In the present study, we tested the protective effect of 3,4,5,6-tetrahydroxyxanthone, a synthetic xanthone derivative, on myocardial ischemia-reperfusion injury in rats. Ischemia-reperfusion injury was induced by 30 min of global ischemia and 30 min of reperfusion in isolated rat hearts or 30 min coronary artery occlusion and 120 min reperfusion in vivo, respectively. Heart rate, coronary flow (CF), left ventricular pressure (LVP), and its first derivative (+/- dp/dt (max)) were recorded, and the activity of creatine kinase in coronary effluent and tumor necrosis factor-alpha (TNF-alpha) content in myocardial tissues were measured in vitro. The activity of serum creatine kinase, the level of TNF-alpha and interleukin-6 (IL-6), and myocardial infarct size were measured in vivo. 3,4,5,6-tetrahydroxyxanthone (30, 100 or 300 microM) caused a significant improvement of cardiac function (LVP and +/- dp/dt (max)) and a decrease in the release of creatine kinase in coronary effluent as well as the level of TNF-alpha in myocardial tissues in vitro. 3,4,5,6-tetrahydroxyxanthone (0.5 or 1.0 mg/kg, i.v.) also markedly decreased infarct size and the release of creatine kinase and TNF-alpha, and increased serum IL-6 level in vivo. These res...Continue Reading

Citations

Apr 1, 2009·Expert Opinion on Drug Metabolism & Toxicology·Carol Wadham, Arduino A Mangoni
May 31, 2014·European Journal of Pharmacology·Anna RapaczHenryk Marona
Jun 5, 2004·Cardiovascular Drug Reviews·De-Jian JiangYuan-Jian Li

❮ Previous
Next ❯